Huge upside potential for sure.
Okomoto being the best seller in Japan, I think the market and analysts have underestimated the revenue that can be generated in FY18 from the vivagel line up alone before DEP is available for pharmaceuticals to use for renewing the patency of their existing chemo drugs. Big pharma will love it for the fact that using DEP will cut a lot of their R&D cost. I am banking on SPL for its' future dividend.
But knowing the downside risk is always paramount for me.
Anyone has the latest Bell potter research? Mind sharing?
FY17 Revenue and Vivagel condom Royalty, page-4
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
9.7¢ |
Change
-0.001(1.02%) |
Mkt cap ! $40.48M | |||
| Open | High | Low | Value | Volume |
| 9.6¢ | 10.0¢ | 9.6¢ | $5.703K | 58.16K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 100000 | 9.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 9.8¢ | 20000 | 1 |
View Market Depth
| Last trade - 15.41pm 11/10/2024 (20 minute delay) ? |
| SPL (ASX) Chart |